These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Experimental animal modeling for immuno-oncology. Li QX; Feuer G; Ouyang X; An X Pharmacol Ther; 2017 May; 173():34-46. PubMed ID: 28167217 [TBL] [Abstract][Full Text] [Related]
45. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481 [TBL] [Abstract][Full Text] [Related]
46. Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. Mer AS; Ba-Alawi W; Smirnov P; Wang YX; Brew B; Ortmann J; Tsao MS; Cescon DW; Goldenberg A; Haibe-Kains B Cancer Res; 2019 Sep; 79(17):4539-4550. PubMed ID: 31142512 [TBL] [Abstract][Full Text] [Related]
47. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339 [TBL] [Abstract][Full Text] [Related]
48. In Vivo Pharmacology Models for Cancer Target Research. Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023 [TBL] [Abstract][Full Text] [Related]
49. Generation of stable PDX derived cell lines using conditional reprogramming. Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548 [TBL] [Abstract][Full Text] [Related]
50. Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Wang Y; Wang JX; Xue H; Lin D; Dong X; Gout PW; Gao X; Pang J Differentiation; 2016; 91(4-5):15-9. PubMed ID: 26547391 [TBL] [Abstract][Full Text] [Related]
51. Human reconstructed skin xenografts on mice to model skin physiology. Salgado G; Ng YZ; Koh LF; Goh CSM; Common JE Differentiation; 2017; 98():14-24. PubMed ID: 29059535 [TBL] [Abstract][Full Text] [Related]
52. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002 [TBL] [Abstract][Full Text] [Related]
53. Humanized Mice for the Study of Immuno-Oncology. De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656 [TBL] [Abstract][Full Text] [Related]
54. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644 [TBL] [Abstract][Full Text] [Related]
55. The role of mouse tumour models in the discovery and development of anticancer drugs. Ireson CR; Alavijeh MS; Palmer AM; Fowler ER; Jones HJ Br J Cancer; 2019 Jul; 121(2):101-108. PubMed ID: 31231121 [TBL] [Abstract][Full Text] [Related]
56. Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives. Zhang ZY; Sun SY Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Dec; 39(6):617-623. PubMed ID: 34859620 [TBL] [Abstract][Full Text] [Related]
57. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments. Zarzosa P; Navarro N; Giralt I; Molist C; Almazán-Moga A; Vidal I; Soriano A; Segura MF; Hladun R; Villanueva A; Gallego S; Roma J Clin Transl Oncol; 2017 Jan; 19(1):44-50. PubMed ID: 27718156 [TBL] [Abstract][Full Text] [Related]
58. Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. Davies AH; Wang Y; Zoubeidi A Mol Cell Endocrinol; 2018 Feb; 462(Pt A):17-24. PubMed ID: 28315377 [TBL] [Abstract][Full Text] [Related]
59. Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism. Henderson CJ; McLaren AW; Kapelyukh Y; Wolf CR F1000Res; 2022; 11():1081. PubMed ID: 37065929 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]